Daewoong003090.KS
本公司簡介的中文翻譯準備中。以下為英文原文。
關於Daewoong
Daewoong Co. is the listed holding company at the head of the Daewoong group, a pharmaceutical enterprise associated with the founding Yoon family. Its principal holding is a controlling stake in Daewoong Pharmaceutical, the group's drug developer and manufacturer, with additional affiliates active in areas such as biologics and animal health. Income at the holding level combines dividends from subsidiaries with brand royalties and management service fees charged across the group. The setup follows a pattern common among Korean pharmaceutical families that converted founder-run drugmakers into two-tier listed structures separating control from daily operations.
Valuation relative to the listed operating subsidiary is the constant frame: the holding company generally trades at a discount to the estimated worth of its stakes, and the width of that gap is where the debate lives. Because cash arrives as dividends and royalties, subsidiary payout decisions govern the holding company's flexibility, including its own dividend. Family control concentrated at this level makes it the locus of succession planning and any ownership reshuffling. Investors wanting direct exposure to the toxin and new-drug story typically prefer the operating company; this vehicle appeals mainly on discount arguments.
Daewoong Co. is the surviving original entity of the pharmaceutical business that Yoon Young-hwan built after acquiring a small postwar drug company in the 1960s. When the group converted to a holding structure in 2002, early among Korean pharmaceutical families, the historic corporation kept its listing and became the control vehicle, while drugmaking moved to the newly created Daewoong Pharmaceutical. The founder's sons took over leadership across the group, and the holding company came to oversee affiliates in generic manufacturing, biologics ventures, and animal health alongside its core stake in the flagship drugmaker.
Beyond its pharmaceutical stake, the parent consolidates operating affiliates that give it business substance of its own: Daewoong Bio supplies active ingredients and finished generics, while ventures in biologics and animal medicine extend the footprint. The parent's decisions determine how toxin and new-drug profits are recycled across these units, making it the group's capital-allocation desk. As the family's control vehicle, it is also where stake changes, inheritance planning, and boardroom arrangements register first, giving its share register a significance beyond day-to-day operations. For outside investors, the entity functions in practice as a levered, discounted mirror of the group's pharmaceutical fortunes.
公司簡介由LineVest編輯部撰寫。屬新聞報導，非投資建議。 委託撰寫Daewoong的DART完整報告 →
Daewoong相關報導
1篇文章
常見問題
What does Daewoong do?
Daewoong Co. is the holding company of the Daewoong pharmaceutical group. It controls Daewoong Pharmaceutical, the main drugmaker, and consolidates affiliates in active ingredients, generics, biologics, and animal health. Its income comes from subsidiary dividends, brand royalties, and management service fees.
Who controls Daewoong?
The founding Yoon family controls Daewoong Co., with the sons of founder Yoon Young-hwan holding leadership and ownership positions built up since the 2002 holding conversion. The company serves as the family's control vehicle over Daewoong Pharmaceutical and the wider group of affiliates.
How can foreign investors get exposure to Daewoong?
The holding company's shares trade on the KOSPI market of the Korea Exchange under ticker 003090 and can be bought through brokers with Korean market access. Investors weighing the group can compare it with the separately listed Daewoong Pharmaceutical, ticker 069620, which carries the operating business directly.
答覆為一般資訊之編輯摘要，非投資建議。
深入標題背後
您剛讀到發生了什麼。接下來，讀懂它意味著什麼。
每天早晨的韓國市場 — 免費
LineVest Daily在首爾開盤前送達您的信箱：KOSPI與KOSDAQ關鍵報導、財報、披露與外資流向 — 以簡明英文呈現。免費，無需信用卡。
基於DART原始披露的獨立新聞報導 — 非投資建議。與任何券商無關。